A trial in the West African nation of Guinea has shown an Ebola vaccine developed by Merck and NewLink Genetics offers 100 percent protection after 10 days, according to a Reuters and CNBC.com report.
The vaccine, called rVSV-ZEBOV, has been tested on more than 4,000 people who had been in close contact with someone with Ebola.
In the journal The Lancet, where the trial results were published, the authors called the vaccine "highly efficacious and safe in preventing Ebola virus disease."